What Is Tesofensine?
Tesofensine is a synthetic small-molecule compound developed under the code NS-2330. It belongs to the class of bridged bicyclic compounds.
The compound has been characterized in published pharmacological studies as a triple monoamine reuptake inhibitor.
Research Overview Table
Chemical and Molecular Characteristics
Tesofensine is a nonpeptide small molecule with an 8-azabicyclo[3.2.1]octane scaffold. Its structure contains a 3,4-dichlorophenyl group, an ethoxymethyl substituent, and four defined stereocenters.
The compound differs structurally from peptides because it has no amino acid-chain or peptide backbone. Its defined stereochemistry and compact molecular architecture are important for chemical identification and analytical characterization in laboratory research.
Certificates:
Mechanism of Action Under Investigation
Tesofensine inhibits the reuptake of dopamine, norepinephrine and serotonin through their respective monoamine transporters. PET research demonstrated dose dependent dopamine transporter occupancy, providing direct evidence of interaction with the dopamine transporter.
Blocking monoamine reuptake increases extracellular availability of these neurotransmitters. Published research has investigated subsequent indirect stimulation of α1-adrenoceptor and dopamine D1 receptor pathways as well as changes in dopamine D2/D3 receptor availability. The active metabolite M1 also inhibits the dopamine transporter and may contribute to the overall pharmacological activity. The relative contribution of these pathways remains incompletely defined.
Scientific Research Context
Tesofensine has been studied in laboratory experiments, animal research, pharmacokinetic studies, PET investigations, and clinical trials. Early papers examined its pharmacological properties and metabolism. Later studies moved into human research, including phase II trials. The published literature now contains both preclinical and clinical work on the compound.
Tesofensine Biology and Biological Pathways
Primary Biological Function
Tesofensine is a synthetic compound and does not have a recognized physiological function. The biological systems examined in its research are mainly central monoaminergic signaling and neural regulation of energy balance. Dopamine, norepinephrine, and serotonin are established neurotransmitter systems involved in CNS signaling.
Relevant Metabolic or Signaling Pathways
Research involving Tesofensine has examined dopaminergic, noradrenergic and serotonergic signaling together with neural circuits involved in energy balance. Recent work has also examined GABAergic signaling in the lateral hypothalamus. These pathways are studied because they connect neurotransmitter activity with central regulation of feeding and metabolic state.
Tissue-Specific Biology
The striatum is relevant to Tesofensine research because of its high density of dopamine transporters. PET studies have used this region to examine transporter distribution. Research has also examined the lateral hypothalamus, where GABAergic neurons form part of the neural circuits involved in feeding behavior.
Experimental Biomarkers
Published studies have used several biological readouts, including dopamine transporter occupancy, monoamine concentrations, dopamine receptor availability, Tesofensine and M1 plasma concentrations, glucose, insulin and lipid measurements. These markers allow researchers to characterize neural, pharmacokinetic, and metabolic changes associated with experimental studies.
Laboratory Investigation Methods
Published Tesofensine studies have used PET imaging, in vitro transporter assays, in vivo microdialysis, pharmacokinetic analysis and electrophysiological recording. More recent work also used optogenetic activation and chemogenetic silencing to examine defined hypothalamic neurons.
Experimental Models Used in Published Research
Published Tesofensine studies have included diet-induced obese rats, Wistar rats, mice, and genetically modified mouse lines. The models differ in species, strain, metabolic state, and genetic background. These differences limit direct comparison between studies and restrict how closely preclinical findings can represent human biology.
Diet-Induced Obese Rats
Diet-induced obese rats have limitations related to the specific diet, feeding period, strain and experimental conditions used to produce obesity. These factors can produce differences between studies. The model also represents diet-induced obesity under controlled laboratory conditions rather than the wider biological variation seen in humans.
Wistar Rats
Adult male Wistar rats were the animal model in the cited Tesofensine study. The main limitation is the use of one rat strain and one sex, which restricts representation of biological variation across sexes and strains and limits direct translation of findings to humans.
NMRI Mice
NMRI mice were used as an experimental model in a pharmacokinetic and pharmacodynamic study of Tesofensine and M1. A stated limitation was the uncertainty in predicting human effects from mouse data, particularly because M1 had not been administered to humans at the time of the study.
Vgat-ChR2 and Vgat-IRES-Cre Mice
Vgat-ChR2 and Vgat-IRES-Cre are transgenic mouse models targeting GABAergic neurons. Their limitation is that genetic targeting isolates a defined neuronal population and does not capture the full diversity of lateral hypothalamic neurons. The study also could not exclude effects from other GABAergic populations or an unidentified cell population.
Tesofensine Published Research
Monoamine Transporter Pharmacology
Published studies have examined Tesofensine across the dopamine, norepinephrine, and serotonin transporter systems, including monoamine reuptake in laboratory assays and dopamine transporter occupancy through PET imaging in humans.
Pharmacokinetics and Metabolism
Research has examined the pharmacokinetic properties of Tesofensine and its major metabolite M1, including absorption, distribution, elimination, concentration–time relationships and pharmacokinetic modeling. More recent work has investigated Tesofensine metabolism and urinary elimination using LC-HRMS.
Energy Metabolism and Appetite
Human studies have investigated Tesofensine in relation to appetite, satiety, energy expenditure, fat oxidation, physical activity, body weight and body composition. Separate clinical studies have examined changes in appetite over longer observation periods.
Central Nervous System Research
Published studies have examined Tesofensine in central nervous system research, including clinical investigations in Parkinson’s disease and Alzheimer’s disease, along with studies of neurological pharmacology in human subjects.
Hypothalamic Neural Circuit Research
Recent preclinical research has investigated Tesofensine in lateral hypothalamic neural circuits, including GABAergic neuronal populations. Researchers have examined neuronal activity and circuit-level responses using electrophysiological, optogenetic, and chemogenetic approaches.
Cardiovascular Research
Researchers have examined the relationship between Tesofensine exposure and heart rate, blood pressure and sympathetic cardiovascular responses in preclinical studies. These investigations have also examined the involvement of adrenergic and angiotensin-related signaling.
Subjective and Abuse-Related Effects
A controlled human study investigated subjective and objective effects of Tesofensine in recreational stimulant users. The research compared Tesofensine with placebo and established pharmacological comparators to characterize its subjective and behavioral profile.
Human Urinary Metabolism
Recent research has investigated the metabolism, urinary excretion and analytical detection of Tesofensine in humans. The study used in vitro metabolism experiments together with LC-HRMS analysis of urine to characterize metabolites and their elimination profiles.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The published Tesofensine literature includes both preclinical and human studies. Animal and laboratory research forms a substantial part of the evidence, but controlled clinical trials have also been reported. Therefore, describing the evidence as predominantly preclinical would not accurately reflect the published record.
Human Clinical Evidence
Human research includes randomized clinical studies in Parkinson’s disease, Alzheimer’s disease, and obesity, along with PET and pharmacokinetic investigations. Most clinical studies were relatively short and several were phase II trials. The published record does not provide the same depth of evidence as a large, long-term clinical development program.
Species Differences
Tesofensine research includes both animal and human studies, but the available preclinical pharmacokinetic data come from mice. Tesofensine and its M1 metabolite showed species-specific pharmacological and metabolic characteristics, while the extent to which these findings apply to humans cannot be established from the mouse data alone.
Study Design Limitations
The published clinical studies include relatively short controlled periods. The 24-week phase II obesity trial had incomplete follow-up, with 161 of 203 randomized participants completing the study. A later 24-week extension was open-label and uncontrolled, with no concurrent placebo group. These design features limit interpretation of longer-term findings.
Independent Replication
Independent replication remains limited in the published Tesofensine literature. Several studies arose from the same development program, while fewer reports provide separate confirmation by unrelated research groups. This limits assessment of how consistently findings can be reproduced across different laboratories and study settings.
Long-Term Evidence
Controlled long-term evidence remains limited. A study continued for another 24 weeks after the initial randomized period, but that phase was open-label and lacked a concurrent control group. This reduces the amount of controlled evidence available beyond the initial 24-week period.
Analytical Documentation
Analytical verification of Tesofensine can combine chromatographic and spectrometric methods. Published studies measured Tesofensine and M1 using validated HPLC-MS/MS, while recent work used LC-HRMS/MS to identify urinary metabolites.
HPLC can assess chromatographic purity and separate the parent compound from related substances. LC-MS provides molecular-mass data for identity confirmation and metabolite analysis. NMR may be used where additional structural confirmation is appropriate.
A Certificate of Analysis (CoA) should link the material to its specific batch and document compound identity, purity, testing date, and analytical method. The Broad Payments requirements also call for a batch-specific third-party CoA and HPLC-preferred testing.
Storage and Laboratory Handling
Store Tesofensine at 2–8°C. Keep the material in its original container with the label intact and avoid unnecessary exposure to temperatures outside the specified range. Clean handling conditions can help limit contamination during routine laboratory work.
Laboratory handling should be carried out by qualified personnel using suitable chemical-handling practices. Keep the container closed when not in use and use clean equipment when transferring material. Tesofensine is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.